Shi Woda, Song Jianxiang, Wang Wencai, Zhang Yajun, Zheng Shiying
Department of Cardiothoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China.
Department of Cardiothoracic Surgery, The Third People's Hospital, Yancheng, Jiangsu 224001, P.R. China.
Mol Med Rep. 2024 Jan;29(1). doi: 10.3892/mmr.2023.13130. Epub 2023 Nov 24.
Following the publication of this paper, it was drawn to the Editor's attention by a concerned reader that the control data in Fig. 2B and C on p. 7332, showing immunofluorescence and migration assay experiments respectively, were strikingly similar to data appearing in different form in another article which was written by different authors at different research institutes [Tian L, Shen D, Li X, Shan X, Wang X, Yan Q and Liu J: Ginsenoside Rg3 inhibits epithelial‑mesenchymal transition (EMT) and invasion of lung cancer by down‑regulating FUT4. Oncotarget 7: 1619‑1632, 2016]. Owing to the fact that the contentious data in the above article had already been published prior to its submission to , the Editor has decided that this paper should be retracted from the Journal. The authors were asked for an explanation to account for these concerns, but the Editorial Office did not receive a reply. The Editor apologizes to the readership for any inconvenience caused. [Molecular Medicine Reports 16: 7329‑7336, 2017; DOI: 10.3892/mmr.2017.7517].
在本文发表后,一位关注此事的读者提醒编辑注意,第7332页图2B和C中的对照数据分别显示免疫荧光和迁移分析实验,与另一篇由不同研究机构的不同作者撰写的文章中以不同形式出现的数据惊人地相似[田L,沈D,李X,单X,王X,严Q和刘J:人参皂苷Rg3通过下调FUT4抑制肺癌的上皮-间质转化(EMT)和侵袭。Oncotarget 7:1619-1632,2016]。由于上述文章中有争议的数据在提交给本期刊之前已经发表,编辑决定将本文从该期刊撤回。已要求作者对这些问题作出解释,但编辑部未收到答复。编辑就由此造成的任何不便向读者表示歉意。[分子医学报告16:7329-7336,2017;DOI:10.3892/mmr.2017.7517]